DESCRIPTION OF THE SHARE BUYBACK PROGRAM & RESUMPTION OF THE LIQUIDITY CONTRACT - Seite 3

The share buyback program may be carried out at any time during the eighteen months following the Board of Directors meeting date on June 22, 2020 at which it was authorized, namely until December 22, 2021.

In accordance with Article 241-2, II of the AMF's General Regulations, while the share buyback program is in process, any significant change in any of the information provided in sections 3, 4, and 5 above will be publicly disclosed without delay, by the methods specified in Article 221-3 of the AMF's General Regulations.

RESUMPTION OF THE LIQUIDITY CONTRACT AND END OF THE STABILIZATION PERIOD

The liquidity contract related to Inventiva shares, which complies with the AMAFI code of ethics and approved by the AMF on March 21, 2011, entered into between Inventiva and Kepler Cheuvreux on January 19, 2018, as amended by an amendment dated February 6, 2019 and tacitly renewable, will expire on December 31, 2020 and will be tacitly renewed.

Inventiva announces today the resumption of this liquidity contract, which was suspended in the context of the initial public offering of Inventiva's shares in the form of American Depositary Shares on the Nasdaq, as of today. The period for the exercise of the overallotment option lasted from July 8 to August 7, 2020. The underwriters of the initial public offering, acting in the name and on behalf of Inventiva, have put an end to the stabilization period, as of today, and have not exercised the overallotment option.

As of August 7, 2020, the following means are allocated to the liquidity account for the execution of this contract:

• 14,361 Inventiva shares held on behalf of Inventiva,
   
• €995,431.05.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.